194 related articles for article (PubMed ID: 36982591)
1. A Liquid-Liquid Phase Separation-Related Index Associate with Biochemical Recurrence and Tumor Immune Environment of Prostate Cancer Patients.
You Q; Chen JY; Wu XH; Xue YT; Sun JB; Wei Y; Zheng QS; Xue XY; Chen DN; Xu N
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982591
[TBL] [Abstract][Full Text] [Related]
2. A Novel Ferroptosis-Based Molecular Signature Associated with Biochemical Recurrence-Free Survival and Tumor Immune Microenvironment of Prostate Cancer.
Ke ZB; You Q; Sun JB; Zhu JM; Li XD; Chen DN; Su L; Zheng QS; Wei Y; Xue XY; Xu N
Front Cell Dev Biol; 2021; 9():774625. PubMed ID: 35071228
[No Abstract] [Full Text] [Related]
3. A radiation resistance related index for biochemical recurrence and tumor immune environment in prostate cancer patients.
Ke ZB; You Q; Chen JY; Sun JB; Xue YT; Zhuang RB; Zheng QS; Chen YH; Wei Y; Sun XL; Xue XY; Xu N
Comput Biol Med; 2022 Jul; 146():105711. PubMed ID: 35701253
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
[TBL] [Abstract][Full Text] [Related]
5. Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy.
Su Q; Liu Z; Chen C; Gao H; Zhu Y; Wang L; Pan M; Liu J; Yang X; Tian J
Cancer Med; 2021 Sep; 10(18):6492-6502. PubMed ID: 34453418
[TBL] [Abstract][Full Text] [Related]
6. Metabolic syndrome-related prognostic index: Predicting biochemical recurrence and differentiating between cold and hot tumors in prostate cancer.
Ren C; Wang Q; Wang S; Zhou H; Xu M; Li H; Li Y; Chen X; Liu X
Front Endocrinol (Lausanne); 2023; 14():1148117. PubMed ID: 37033267
[TBL] [Abstract][Full Text] [Related]
7. Significance of liquid-liquid phase separation (LLPS)-related genes in breast cancer: a multi-omics analysis.
Xie J; Chen L; Wu D; Liu S; Pei S; Tang Q; Wang Y; Ou M; Zhu Z; Ruan S; Wang M; Shi J
Aging (Albany NY); 2023 Jun; 15(12):5592-5610. PubMed ID: 37338518
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitination-Related Molecular Subtypes and a Novel Prognostic Index for Bladder Cancer Patients.
Cai H; Chen H; Huang Q; Zhu JM; Ke ZB; Lin YZ; Zheng QS; Wei Y; Xu N; Xue XY
Pathol Oncol Res; 2021; 27():1609941. PubMed ID: 34776794
[No Abstract] [Full Text] [Related]
9. A tumor-associated macrophages related model for predicting biochemical recurrence and tumor immune environment in prostate cancer.
Chen JY; Huang XY; Lin F; You Q; Xue YT; Lin B; Zheng QS; Wei Y; Xue XY; Li XD; Chen DN; Xu N
Genomics; 2023 Sep; 115(5):110691. PubMed ID: 37516327
[TBL] [Abstract][Full Text] [Related]
10. An integrative multi-omics analysis based on liquid-liquid phase separation delineates distinct subtypes of lower-grade glioma and identifies a prognostic signature.
Zheng J; Wu Z; Qiu Y; Wang X; Jiang X
J Transl Med; 2022 Jan; 20(1):55. PubMed ID: 35093128
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy.
Luo Y; Liu X; Lin J; Zhong W; Chen Q
Math Biosci Eng; 2022 Aug; 19(11):11345-11366. PubMed ID: 36124593
[TBL] [Abstract][Full Text] [Related]
12. Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer.
Liu B; Li X; Li J; Jin H; Jia H; Ge X
Dis Markers; 2020; 2020():8860788. PubMed ID: 33101546
[TBL] [Abstract][Full Text] [Related]
13. Development of a ferroptosis-based molecular markers for predicting RFS in prostate cancer patients.
Chen J; Zhang L; Luo Y; Tan C; Hu H; Jiang Y; Xi N; Zeng Q; Peng H
Sci Rep; 2023 Dec; 13(1):22804. PubMed ID: 38129557
[TBL] [Abstract][Full Text] [Related]
14. A novel 13 RNA binding proteins (RBPs) signature could predict prostate cancer biochemical recurrence.
Xing Q; Liu S; Luan J; Wang Y; Ma L
Pathol Res Pract; 2021 Sep; 225():153587. PubMed ID: 34419719
[TBL] [Abstract][Full Text] [Related]
15. A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer.
Ren L; Yang X; Wang W; Lin H; Huang G; Liu Z; Pan J; Mao X
Front Genet; 2023; 14():1096783. PubMed ID: 36911392
[No Abstract] [Full Text] [Related]
16. A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer.
Hu D; Cao Q; Tong M; Ji C; Li Z; Huang W; Jin Y; Tong G; Wang Y; Li P; Zhang H
BMC Med Genomics; 2022 Feb; 15(1):24. PubMed ID: 35135561
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of an E2F-related gene signature for predicting recurrence-free survival in human prostate cancer.
Yang C; Chen L; Niu Q; Ge Q; Zhang J; Tao J; Zhou J; Liang C
Cancer Cell Int; 2022 Dec; 22(1):382. PubMed ID: 36471446
[TBL] [Abstract][Full Text] [Related]
18. A Novel Four Mitochondrial Respiration-Related Signature for Predicting Biochemical Recurrence of Prostate Cancer.
Xia Z; Liu H; Fan S; Tu H; Jiang Y; Wang H; Gu P; Liu X
J Clin Med; 2023 Jan; 12(2):. PubMed ID: 36675580
[TBL] [Abstract][Full Text] [Related]
19. A Novel Set of Immune-associated Gene Signature predicts Biochemical Recurrence in Localized Prostate Cancer Patients after Radical Prostatectomy.
Luan JC; Zhang QJ; Zhao K; Zhou X; Yao LY; Zhang TT; Zeng TY; Xia JD; Song NH
J Cancer; 2021; 12(12):3715-3725. PubMed ID: 33995646
[No Abstract] [Full Text] [Related]
20. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
